Aqueous Suppressants for pediatric Ahmed Valve.

Early and prolonged administration of aqueous suppressants for prevention of hyperencapsulation with Ahmed Valve in refractory pediatric glaucoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201901915134088

Enrollment

Registered

2019-01-21

Start date

2015-10-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases

Interventions

Aqueuos supressants

Prologned Administration of Aqueous suppressants

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients younger than 16 years and diagnosed with refractory pediatric glaucoma including congenital glaucoma, juvenile glaucoma, aphakic/Pseudophakic glaucoma and glaucoma in vitrectomized eyes

Exclusion criteria

Exclusion criteria: Exclusion criteria were previous AGV implantation, co-existing corneal pathology, inability to measure IOP accurately or primary tube failure.

Design outcomes

Primary

Measure	Time frame
Presence or Absence of Hyperencapsulation phase which is defined as as thickened, vascularized bleb over AGV with IOP = 21 mmHg in absence of tube malfunction. Primary tube failure was defined as tube malfunction or obstruction with aqueous drainage failure. Rescue needling of the bleb was postponed after 3 months post-operatively.	—

Secondary

Measure	Time frame
Adverse reactions	—

Countries

Egypt

Contacts

Public ContactMahmoud Rateb

Lecture of Ophthalmology Assiut University

rateb@aun.edu.eg+201008348480

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026